尼洛替尼与伊马替尼一线治疗初诊慢性髓性白血病慢性期患者的比较
该回顾性研究纳入524例初诊CML-CP患者,比较尼洛替尼(85例)与伊马替尼(439例)一线治疗的疗效与安全性。尼洛替尼组更快、更高比例获得CCyR、MMR和MR(4.5),并显著改善FFS,但两组6年PFS和OS无显著差异;严重血液学不良反应与TKI种类无关。
要点
- 尼洛替尼一线治疗较伊马替尼更快、更高比例获得CCyR、MMR和MR(4.5)。
- 尼洛替尼组6年FFS显著优于伊马替尼组,但PFS和OS无显著差异。
- 严重血液学不良反应与TKI种类无关;Sokal评分影响疗效与生存。
核心结论
- 对于初诊CML-CP患者,尼洛替尼一线治疗较伊马替尼更快、更高比例获得细胞遗传学和深层分子学反应,并显著改善FFS。
研究设计与样本
- 回顾性分析2006年1月至2018年12月连续收治的初诊CML-CP患者,共524例,伊马替尼组439例(83.8%),尼洛替尼组85例(16.2%)。
主要发现
- 中位TKI治疗57(范围3~153)个月,尼洛替尼组CCyR(P=0.011)、MMR(P=0.001)和MR(4.5)(P=0.046)获得率均显著高于伊马替尼组。
- 两组6年FFS、PFS和OS率差异均无统计学意义(P>0.05)。
- 多因素分析显示伊马替尼是获得CCyR(OR=0.6,95%CI 0.5~0.8,P=0.001)、MMR(OR=0.6,95%CI 0.5~0.8,P=0.001)和MR(4.5)(OR=0.6,95%CI 0.5~0.9,P=0.032)的不利因素,并与较差FFS(OR=1.9,95%CI 1.0~3.4,P=0.041)显著相关。
- Sokal中/高危与较低的细胞遗传学和分子学反应获得率及较差的FFS、PFS、OS相关。
- 男性、诊断时WBC≥100×10(9)/L或HGB<120 g/L与较低的细胞遗传学和分子学反应获得率和(或)较差FFS显著相关。
关键数值与推荐
- 尼洛替尼组较伊马替尼组更年轻(P=0.019),Sokal中/高危(P<0.001)、WBC≥100×10(9)/L(P<0.001)、HGB<120 g/L(P<0.001)、骨髓原始细胞(P=0.026)、脾脏可触及肿大(P<0.001)比例更高,诊断至TKI治疗间隔更长(P=0.003)。
- 严重白细胞减少和血小板减少与药物种类无关。
临床怎么用
- 初诊CML-CP患者选择一线TKI时,尼洛替尼可获得更快更深的分子学反应并改善FFS,但需结合患者风险评分、基线特征及耐受性个体化决策。
局限性
- 为单中心回顾性研究,尼洛替尼组样本量较小(85例)且基线特征与伊马替尼组存在显著差异,可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To compare the cytogenetic and molecular responses, outcomes and severe hematologic toxicity of nilotinib and imatinib as frontline therapy in newly diagnosed patients with chronic myeloid leukemia in chronic phase (CML-CP) . Methods: Newly diagnosed CML-CP patients were consecutively recruited from January 2006 to December 2018 who received nilotinib and imatinib as first-line treatment. Clinical data were retrospectively analyzed. Results: A total of 524 patients were classified into 439 (83.8%) receiving imatinib and 85 (16.2%) receiving nilotinib. Comparing with imatinib group, patients in nilotinib group were much younger (P=0.019) and more with intermediate and high Sokal risks (P<0.001) , WBC ≥100×10(9)/L (P<0.001) , HGB<120 g/L (P<0.001) , blast cells in bone marrow (P=0.026) , splenomegaly (P<0.001) by physical examination at diagnosis, and longer interval from diagnosis to TKI treatment (P=0.003) . With a median TKI duration of 57 (range 3-153) months, the probabilities of complete cytogenetic response (CCyR) (P=0.011) , major molecular response (MMR) (P=0.001) and MR(4.5) (P=0.046) were much higher in nilotinib group than those in imatnib according to each risk group. There is no statistical significance on probabilities of failure free survival (FFS) , progression free survival (PFS) and overall survival (OS) at 6 years between the two groups. Multivariate analyses showed that imatinib was an adverse factor associated with achieving CCyR (OR=0.6, 95% CI 0.5-0.8, P=0.001) , MMR (OR=0.6, 95% CI 0.5-0.9, P=0.032) and MR(4.5) (OR=0.6, 95%CI 0.5-0.9, P=0.032) and poor FFS (OR=1.9, 95%CI 1.0-3.4, P=0.041) . In addition, Sokal score was an independent factor affecting cytogenetic and molecular responses, treatment failure, disease progression and survival. Male, WBC ≥100×10(9)/L or HGB<120 g/L at diagnosis were significantly associated with lower cytogenetic and molecular response rates and/or poor FFS. The severe hematologic adverse events were not associated with different TKIs. Conclusions: Nilotinib reaches to the faster and deeper cytogenetic and molecular responses and significantly improves FFS than imatinib in newly diagnosed patients with CML-CP. 目的: 比较尼洛替尼与伊马替尼一线治疗初发慢性髓性白血病(CML)慢性期(CP)患者的细胞遗传学和分子学反应获得率、预后及血液学不良反应的差异。 方法: 回顾性分析2006年1月至2018年12月诊治的初诊且尼洛替尼或伊马替尼作为一线治疗的CML-CP患者的连续病例资料。 结果: 共524例患者纳入研究,其中伊马替尼治疗组439例(83.8%),尼洛替尼治疗组85例(16.2%)。与伊马替尼组相比,尼洛替尼组患者更为年轻(P=0.019),Sokal积分中/高危患者(P<0.001)、WBC ≥100×10(9)/L(P<0.001)、HGB<120 g/L(P<0.001)、骨髓原始细胞(P=0.026)、脾脏可触及肿大(P<0.001)比例显著增高,诊断距服用TKI时间显著延长(P=0.003)。中位治疗57(3~153)个月,与伊马替尼组相比,尼洛替尼组患者更快、更高比例获得完全细胞遗传学反应(CCyR)(P=0.011)、主要分子学反应(MMR)(P=0.001)和分子学反应4.5(MR(4.5))(P=0.046)。两组间6年无治疗失败生存(FFS)、无疾病进展生存(PFS)和总生存(OS)率差异均无统计学意义(P>0.05)。多因素分析显示,服用伊马替尼是获得CCyR(OR=0.6,95% CI 0.5~0.8,P=0.001)、MMR(OR=0.6,95%CI 0.5~0.8,P=0.001)和MR(4.5)(OR=0.6,95%CI 0.5~0.9,P=0.032)的不利因素,并与较差的FFS(OR=1.9,95%CI 1.0~3.4,P=0.041)显著相关。Sokal中/高危与较低的细胞遗传学和分子学反应获得率和较差的FFS、PFS、OS相关。此外,男性、诊断时WBC ≥100×10(9)/L或HGB<120 g/L也与较低的细胞遗传学和分子学反应获得率和(或)较差的FFS显著相关。严重的白细胞减少和血小板减少与药物种类无关。 结论: 对于初诊CML-CP患者,与伊马替尼相比,尼洛替尼一线治疗能够更快、更早地获得细胞遗传学反应和深层分子学反应,并显著改善FFS。.
引用
- Yu L, Qin YZ, Lai YY, et al. [Comparison of nilotinib vs imatinib as frontline therapy in newly diagnosed patients with chronic myeloid leukemia in chronic phase]. Zhonghua Xue Ye Xue Za Zhi. 2019. PMID: 32023729. doi:10.3760/cma.j.issn.0253-2727.2019.12.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。